Completion of Placing and TVR

Block Listing Six Monthly Return

Avacta presents preclinical data at AACR-NCI-EORTC

Notice of Investor Presentation

Avacta Presents Phase 1a Data for Faridoxorubicin

Equity fundraise of £16 million

Avacta to present data at EORTC-NCI-AACR

Interim Half Year Results 2025

Notice of Interim Results

Shortlisted for AIM Awards Technology of the Year

Avacta completes sale of Coris Bioconcept

Amendments to Convertible Bond + equity fundraise

Equity fundraise of £3.25 million

Result of AGM

Q2 2025 Business Update

Management Team Appointments

Appointment of Zeus Capital as Joint Broker

New Response in Phase 1b Trial

Posting of Annual Report and Revised Notice of AGM

Preliminary Full Year 2024 Results

Avacta Change in Prelim Date Part 2

Board appointments

Update on timing of preliminary results

Notice of Results

Investor Webinar

Block Listing Application to AIM

Board change

Avacta presents preclinical data at AACR

Avacta presents data from lead candidate at AACR

Issue of Equity and Total Voting Rights

Avacta Quarterly Update

Avacta Announces Presentations at AACR

Avacta Completes Launch Diagnostics Sale

Avacta to Present at Leerink Healthcare Conference

Avacta announces data update for AVA6000

Avacta to sell Launch Diagnostics

Appointment of Joint Broker

Issue of Equity and Total Voting Rights

Avacta Announces Data from AVA6000 Phase 1 trial

Avacta Appoints Chief Financial Officer

Completion of Dose Escalation and RDE Arms

R&D Spotlight focusing on pipeline advances

Block Listing Six Monthly Return

Avacta Reports Pipeline Avances at EORTC

Issue of Equity and Total Voting Rights

Avacta and Tempus Enter Strategic Collaboration

Avacta Expands its Pipeline

Avacta appoints Chief Scientific Officer

Avacta Unveils Pipeline Expansion at EORTC 2024

Interim Results

Avacta Reported Updated Phase 1 Data of AVA6000

Notice of Results

Avacta to present clinical data at ESMO Congress

Director/PDMR Shareholdings and TVR

Convertible Bond Payment

Result of AGM

AGM Business Update

Shaun Chilton appointed Non-Executive Chairman

Appointment of Nominated Adviser and Sole Broker

Posting of Annual Report and Notice of AGM

Successful Completion of First Cohort

Board Change

Full Year Results

Block listing Interim Return REPLACEMENT

Block Listing Six Monthly Return

Block Listing Application to AIM

Notice of Results

Issue of Equity and Total Voting Rights

Avacta Reports Data at the AACR Annual Meeting

AVA6000 Abstract Release by AACR

Update on AVA6000 Phase 1a Clinical Trial Progress

Result of General Meeting

Avacta Announces AVA6000 Poster at AACR

Result of REX Retail Offer

Result of Placing

Proposed REX Retail Offer

Proposed Fundraise to progress Therapeutics

Share Incentive Plan/Issue of Equity

Issue of Equity and Total Voting Rights

Appointment of Christina Coughlin

Appointment of Chief Business Officer

ALS-6000-101 Phase 1a Study Data

Shareholder update to review AVA6000 Phase 1a data

Block Listing Six Monthly Return

Issue of Equity and Total Voting Rights

Block Listing Application to AIM

Avacta to present at AACR-NCI-EORTC conference

Interim Results for the Period Ending 30 June 2023

Issue of Equity and Total Voting Rights

Peel Hunt Appointed as Joint Broker

Appointment Dr.Christina Coughlin as a consultant

Successful Completion of Sixth Dose Escalation

Notice of Results

Issue of Equity and Total Voting Rights

Result of Annual General Meeting

Annual General Meeting and Shareholder Event

Completion of Fifth Dose Escalation in AVA6000

Director Appointment

Statement regarding market speculation

AGM and Shareholder Event Detailed Agenda

Second Milestone in AffyXell Joint Venture

Posting of Annual Report and Notice of AGM

Avacta acquires Coris Bioconcept